DE LA CUEVA MENDEZ, G. et al Appln. No. 10/030,706 August 25, 2006

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- eycle progression, in target eukaryotic cells, the method comprising providing within eukaryotic cells ParD kid toxin a bacterial toxin and ParD kis antitoxin an inhibitor of said toxin, optionally an antidote to the toxin wherein both toxin and antidote are proteins, under appropriate control for selective cell cycle inhibition and/or killing of said target cells.
- 2. (Currently Amended) The Amethod according to claim 1 wherein the cells are *in vitro*.
- 3. (Currently Amended) The Amethod according to claim 1 wherein the cells are plant cells.
- 4. (Currently Amended) A-The method according to claim 1 which is therapeutic and carried out on a human or animal body.
  - 5-9 (Cancelled).

DE LA CUEVA MENDEZ, G. et al Appln. No. 10/030,706 August 25, 2006

- 10. (Currently Amended) The Amethod according to claim 1 wherein said toxin is provided within said cells by means of nucleic acid encoding said toxin under control of appropriate control elements for expression.
  - 11. (Cancelled).
- 12. (Currently Amended) TheA method according to claim 1 or 11 comprising providing to said cells said toxin and an antidote to the toxin said antitoxin, wherein both toxin and antidote are proteins, and wherein said control comprises controlling activity of said antidote antitoxin on said toxin to control activity of said toxin on said cells.
- 13. (Currently Amended) The Amethod according to claim 12 wherein ParD kis antitoxin an inhibitor of said toxin, optionally said antidote, is provided within said cells by means of nucleic acid encoding said toxin antitoxin under control of appropriate control elements for expression.
- 14. (Currently Amended) A-The method according to claim 12 wherein selectivity for expression for said toxin within target cells is effected by a combination of (i) up-regulation of toxin production in target cells and (ii) down-regulation of toxin production in non-target cells and/or neutralisation of toxin activity in non-target cells.

DE LA CUEVA MENDEZ, G. et al Appln. No. 10/030,706 August 25, 2006

- 15. (Currently Amended) A-The method according to claim 14 wherein neutralisation of toxin activity in non-target cells is effected by upregulation of antidote antitoxin production in non-target cells.
- 16. (Currently Amended) A-The method according to claim 12 wherein said target cells are tumour cells.
  - 17. (Cancelled).
  - 18. (Withdrawn) A composition comprising:
- (i) a bacterial toxin and an inhibitor of said toxin, optionally an antidote to said toxin wherein both toxin and antidote are proteins, or
- (ii) nucleic acid encoding a bacterial toxin and an inhibitor of said toxin, optionally an antidote to said toxin wherein both toxin and antidote are proteins, for use in a therapeutic method according to claim 4 or 11.
  - 19. (Cancelled).